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Expression quantitative trait loci (eQTL) mapping is a powerful tool for identifying genetic regulatory vari-
ation. However, at present, most eQTLs in humans were identiﬁed using gene expression data from cell
lines, and it remains unknown whether these eQTLs also have a regulatory function in other expression con-
texts, such as human primary tissues. Here we investigate this question using a targeted strategy.
Speciﬁcally, we selected a subset of large-effect eQTLs identiﬁed in the HapMap lymphoblastoid cell lines,
and examined the association of these eQTLs with gene expression levels across individuals in ﬁve
human primary tissues (heart, kidney, liver, lung and testes). We show that genotypes at the eQTLs we
selected are often predictive of variation in gene expression levels in one or more of the ﬁve primary tissues.
The genotype effects in the primary tissues are consistently in the same direction as the effects inferred in the
cell lines. Additionally, a number of the eQTLs we tested are found in more than one of the tissues. Our
results indicate that functional studies in cell lines may uncover a substantial amount of genetic variation
that affects gene expression levels in human primary tissues.
INTRODUCTION
Expression quantitative trait loci (eQTL) mapping studies in
humans are widely used to identify genetic variation that
affects gene regulation—speciﬁcally, transcript levels
(reviewed in 1). The long-term goal of these studies is to elu-
cidate how functional regulatory variation at the DNA level
underlies morphological or physiological variation by using
expression levels as intermediate molecular phenotypes.
To date, many of the surveys of putatively functional regu-
latory variation in humans have been conducted in lympho-
blastoid cell lines (LCLs), rather than primary tissues,
mostly by using the HapMap cell lines (2–6). Cell lines
offer convenience and replicability, and the HapMap cell
lines, in particular, represent the most complete catalog of
human variation (7), a resource that will become even more
useful as the genomes of many of these cell lines are
sequenced as part of the 1000 Genomes project (8).
Thus, cell lines are expected to continue to be integral to
improving our understanding of human regulatory variation.
However, cell lines often carry chromosomal abnormalities
(9), altered methylation patterns (10), may have pronounced
batch effects related to preparation and/or growth rates
(11,12) and the Epstein–Barr virus (EBV) transformation
itself can alter the expression levels of a subset of genes (13).
Furthermore, the modular nature of gene regulation may
allow the genetic architecture of gene expression to vary sub-
stantially over tissues (14,15). For these reasons, work with
cell lines is often criticized as being potentially uninformative
regarding regulatory interactions in primary tissues. Yet, func-
tional assays in LCLs may often be the only feasible approach
(e.g. 16) to further study the potential function of large
number of non-coding loci identiﬁed in recent genetic associ-
ation studies of complex human diseases (17–24).
Indeed, collections of large numbers of primary tissues are
not very common. To date, only a few eQTL studies in
humans have been carried out in primary tissues (including
studies in liver, blood, adipose tissue and brain (25–28)).
These studies, however, provided little information regarding
the overlap of eQTLs found in LCLs and primary tissues.
For one, differences in study designs, platforms, sampling
schemes, and the speciﬁc deﬁnitions of different classes of
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one deﬁnes a cis eQTL) made it difﬁcult to interpret compari-
sons of eQTL mapping results across studies (1). Perhaps due
to these reasons, only two studies of eQTLs in primary tissues
have thus far compared eQTLs across pairs of tissues (25,28),
and only one study (27) has compared their ﬁndings with
eQTL results from the HapMap cell lines, and found only
minimal overlap. We therefore set out to test, using a dedi-
cated study design, whether SNPs identiﬁed as eQTLs in
HapMap LCLs also contribute to functional regulatory vari-
ation in human primary tissues.
When we designed the study, we considered the two primary
strategies that can be used to conﬁrm cis regulatory variation
(29,30): (i) identifying differences in expression levels between
alleles of the same gene (using allele-speciﬁc expression
measurements (31,32)), or (ii) identifying associations between
SNP genotypes and the total expression (i.e. the overall
expression across both alleles) of the gene (2–6,25–28). The
allele-speciﬁc approach is attractive because it allows one to
easilycontrolforenvironmentalandtranseffectswithinindivid-
uals. However, this approach requires one to develop allele-
speciﬁc assays, and is limited to individuals heterozygous at a
SNP within the transcript. Moreover, the assayed SNP must be
in linkage disequilibrium with the causal regulatory variant
(often outside the transcript). In contrast, the eQTL mapping
approachallowsonetouseallavailablesamples(thusincreasing
power) and does not require one to identify additional SNPs
within the expressed transcripts of interest. The eQTL mapping
approachmitigatestransandenvironmentaleffectsbyaveraging
the genotypic affect across individuals.
We thus followed Veyrieras et al. (6) and others and chose
to design an eQTL association study. As we were limited by
the small numbers of samples per primary tissue (10–23 per
tissue), we chose to focus on a subset of previously identiﬁed
large-effect HapMap cis-eQTLs (6) for which we estimate to
have reasonable power to detect an effect on gene expression
levels in the primary tissues, given the genotypes of our
samples (see Materials and Methods for details). We thus
selected 21 cis-eQTLs for investigation, and examined
whether these eQTLs are also associated with variation in
gene expression in one or more of the primary tissues.
RESULTS
In order to test whether eQTLs found in cell lines are also func-
tional in other contexts, we asked whether strong candidate
cis-eQTLs found in the CEU (European-ancestry from Utah,
USA; Centre d’Etude du Polymorphisme Humain collection)
HapMap cell lines can also explain inter-individual variation
in gene expression data from panels of multiple human
primary tissues (13 hearts, 23 kidneys, 18 livers, 20 lungs and
10testes;intotalcomprising84tissuessampledfrom63individ-
uals identiﬁed as Caucasian). As the number of primary tissue
samples available to us is small, we focused on a subset of
eQTLs for which we have reasonable power to detect a regulat-
ory effect in the primary tissues. We chose this subset of eQTLs
usingthefollowingapproach(seeFig.1foranillustrationofour
SNP selection procedure): We ﬁrst focused on cis-eQTLs that
were previously identiﬁed using microarray expression data
from HapMap LCLs (6,33), ignoring trans-acting variants as
their effect sizes tend to be small (26). We then excluded
SNPswithminorallelefrequencies  0.2intheCEUpopulation
(as our primary tissues samples were collected from Cauca-
sians), and excluded all but the one largest-effect eQTL for
each gene (in the original analysis more than one signiﬁcant
cis-eQTL per gene may have been identiﬁed). We further
excluded eQTLsthat were not detectedinalltheHapMappopu-
lations in which the SNP was typed, as eQTLs identiﬁed in mul-
tiple populations are more likely to be true positives, as well as
less likely to result from an artifact particular to a single prep-
aration of cell lines. Finally, we ranked the remaining eQTLs
by their effect sizes, and arbitrarily chose to focus on those
eQTLs for which the genotype explains  19% of the variation
in expression in the CEU population. This series of exclusion
steps resulted in a list of 206 eQTLs.
The next step was to examine whether the speciﬁc genotypes
inour tissue collection would allowus totestthe function ofthe
206 eQTLs. To determine that, we designed multiplex Seque-
nom Mass-Spec genotyping assays for 196 of the 206 SNPs
(we were not able to include 10 SNPs in the multiplex
design), and genotyped these 196 SNPs in all our samples.
We then performed resampling simulations to assess the
power for detection of each of the 196 eQTLs. Speciﬁcally,
we sampled gene expression levels from the HapMap microar-
ray data from a collection of individuals with genotypes that
match the genotypes of our actual primary tissues and asked
what is the proportion of such replicate simulations (for each
tissue-eQTL combination) in which we detect the eQTL. In
other words, we estimated the power to detect the HapMap
eQTL if the only available data was from HapMap cell lines
withthesamegenotypesasthosewehaveinourprimarytissues.
Using the results of the power simulations we selected
21 cis-eQTLs, which we expected to be able to detect in at
least one or more of the primary tissues (see Fig. 1 and Sup-
plementary Material, Table S1). We then proceeded to
measure the expression levels of each of the 21 cis genes in
all tissues using quantitative RT-PCR (see Materials and
Methods). For a subset of these genes, we also conﬁrmed
the original inference from the microarray data using newly
extracted RNA from 9 HapMap cell lines (see Supplementary
Material, Fig. S1).
To test for an association between the genotypes of each
putative eQTL (i.e. a particular SNP) and the expression
level of the cis gene, we used an additive linear model to
analyze the quantitative RT-PCR data from each tissue. We
note that the association between genotype and expression
level may not be additive (e.g. 34). However, in our case,
we focus on eQTLs that showed strong additivity in the
HapMap cell line expression data, and thus simple additive
linear models may be expected to capture most of the associ-
ation between genotypes and expression levels in these cases.
Given a prior expectation of the direction of the genotype
effect based on the HapMap cell-line expression data, we
chose to increase power by constructing the test to be one-sided
in the direction of the predicted genotype effect. Therefore, we
tested for an association of each putative eQTL with gene
expression data from all ﬁve tissues, for a total of 105 tests.
Using this additive association approach, we found that 19 of
the 105 tests were signiﬁcant (at a one-sided P-value , 0.05)
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included both additive and dominance terms in the linear
model(SupplementaryMaterial,TableS2).Withourfalseposi-
tive rate set to 0.05, we have an estimated positive false discov-
ery rate, or pFDR (35), of 14%, suggesting that about 16 of the
eQTLs are expected to be true positives (and we note that based
on permutation tests, our P-values appear well calibrated; see
Materials and Methods).
WedetectedeQTLsinatleastoneprimarytissuefor11ofthe
genes (52%, P-value ¼ 0.003, binomial test, see Materials and
Methods), while ﬁve genes had signiﬁcant eQTLs in more than
one primary tissue (see Fig. 2 and Supplementary Material,
Fig. S4 and Fig. 3A for a speciﬁc example, in which we
detect the eQTL associated with USMG5 in four of ﬁve
tissues). If we relax the stringency of our test to a one-sided
P-value , 0.1 (which may be a reasonable approach given
that all these loci were previously detected as eQTLs in the
LCLs), 67% of the eQTLs are present in at least one tissue.
Moreover, 70 of the 105 tests were in the expected direction
based on the HapMap gene expression data (signiﬁcant by one-
sided sign test; P ¼ 0.0004, null expectation is 52.5). Thus, our
resultsindicate thatputativeeQTLsfoundincelllinescanoften
be detected in one or more primary tissues.
DISCUSSION
Overall, our results show that a large number of eQTLs orig-
inally identiﬁed in the HapMap LCLs can also be detected in
primary tissues, suggesting that studies in cell lines are
helpful for identifying functional regulatory variation.
However, it should be noted that, perhaps not surprisingly,
there are a number of assays for which we expected to have
good power to detect eQTLs, but did not detect one in any of
the tissues that we tested (i.e. Fig. 3B). For example, under
the (admittedly) extreme scenario that all 21 cis-eQTLs are
truly affecting gene regulation in all ﬁve tissues with the same
effect size as seen in the HapMap LCLs, then given our
power calculations, we would expect 96/105 signiﬁcant tests
(atone-sidedP   0.05).Onepossibleexplanationfortheappar-
ent discrepancy between this expectation and our observations
is that eQTLs observed in the LCLs have a systematically
smaller effect sizes in the primary tissues. Indeed, we estimated
that a two-third reduction in effect size (from those observed in
HapMap) is consistent with our observed number of signiﬁcant
tests (see Materials and Methods). A number of factors may
underlie such lower effect sizes. First, the effect sizes can be
over-estimated when the original study is underpowered, due
to the so-called Winner’s Curse (e.g. 36), leading to smaller
observed effect sizes when considering an entirely different
sample of individuals. Second, the true effect size of an eQTL
in a different tissue may tend to be systematically smaller
because we selected the very strongest eQTLs in the ﬁrst
tissue, a biological (rather than statistical) winner’s curse.
That said, perhaps amore obvious explanation for the overall
relativelyloweQTLdetectionrateinourprimarytissuestudyis
biological, namely that certain genetic variants affect
expression levels only in a subset of tissues. Indeed, genes are
Figure 1. Illustration of candidate eQTL selection strategy. (1) In selecting SNPs to test for an association with expression in primary human tissues, we began
with a set of predictions based on a Bayesian analysis of HapMap genotypes and expression data. (2) We narrowed these 11444 eQTL predictions down to 206
based on several criteria, as detailed in the Materials and Methods section. (3) We successfully genotyped 196 of the 206 in the 63 individuals from which we
have tissue samples. (4) For each eQTL in each of the ﬁve tissues, we conducted simulations to estimate power conditional on the actual genotypes of our
samples, using expression data from one of the three HapMap populations. On the basis of these simulations, we chose 15 eQTLs that we estimated to have
80% power in at least six of the 15 population-tissue combinations and at least 65% power in four of the ﬁve tissues using data from CEU. To these 15, we
added six more eQTLs that fell slightly below our cutoffs, but looked promising. (5) We then assayed expression level of the 21 genes using qPCR in all
84 samples. (6) We used linear regressions to determine signiﬁcance of each of the eQTLs in each of the ﬁve human primary tissues.
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part, due to the modular nature of cis-regulatory elements
(15). Thus, although the expression of all assayed genes was
detectedinallﬁvetissues,wedonotknowwhichcis-regulatory
elements are employed in each tissue. For example, under an
alternative scenario, if we assume that each cis-eQTL were
present in exactly one primary tissue with an effect size
similar to that observed in the cell lines, then given our power
calculations, we would expect 23/105 signiﬁcant tests (includ-
ing false positives, at one-sided P   0.05). Our conﬁrmation
rate (19/105) is only somewhat lower than this estimate.
Of course, it remains possible—likely perhaps—that some
eQTLs detected in the LCLs are artifacts, and would never
be seen in primary tissues. We expect that, in actuality, our
observations are accounted for by an unknown combination
of all three explanations, as often is the case in biology.
However, our results and others (37,38) indicate that a non-
negligible fraction of cis variation affects multiple tissues.
To investigate and characterize further how shared is the
genetic basis of variation in gene expression, large-scale,
multiple-tissue studies will be best suited and are imminently
feasible. Importantly, our observations (albeit using limited
sets of genes and samples) are encouraging, as they indicate
that investigations of genetic and regulatory variation in cell
lines can certainly inform our understanding of regulatory
variation in diverse primary tissues.
MATERIALS AND METHODS
Tissue samples and DNA/RNA extraction
We genotyped and assayed gene expression in 84 samples
from ﬁve human tissues: 13 hearts, 23 kidneys, 18 livers,
20 lungs and 10 testes. We had multiple tissues from 11 of
the 63 individuals (kidney and liver from two individuals,
heart and lung from three, heart, liver and lung from one,
heart liver and testes from one and all but testes from four
individuals). All samples are from self-identiﬁed Caucasian
individuals. We note that tissues were sampled from largely
non-overlapping sets of individuals for each tissue type.
Given we are primarily interested in the effect of cis regulat-
ory variation, and not the genetic basis of expression covaria-
tion among tissues, having largely non-overlapping sets of
individuals is preferable to having all tissues from each indi-
vidual because non-overlapping sets will reduce the impact
of individual-speciﬁc effects, such as environmental effects,
which otherwise could confound the analysis. Thus, although
we desired independent sets of individuals we included all
tissues available to us in order to increase power, as the trade-
off is likely to be minimal. The human adult tissue samples
were collected for us by the National Disease Research Inter-
change (NDRI). We extracted DNA from each tissue using the
Qiagen DNeasy Blood & Tissue Kit (Qiagen, Germantown,
MD). RNA was extracted from the tissues using Trizol
(Invitrogen, Carisbad, CA) and ﬁrst strand cDNA was
synthesized using a poly-T oligo and the superscript kit
(Invitrogen, Carisbad, CA).
SNP selection and genotyping
To select which SNPs to genotype in our samples (see Fig. 1),
we used a heuristic that prioritized SNPs based on two criteria:
(i) The ability of the genotype at a SNP to signiﬁcantly explain
expression in at least two of the three HapMap populations
using simple additive linear models and (ii) a minor allele fre-
quency  0.2 in the CEU HapMap population. The motivation
for the latter criterion is that our samples are from individuals
identiﬁed as Caucasian and by conditioning on a minor allele
frequency above 0.2 we increase the odds that the SNPs
chosen will segregate among our samples in as many tissues
Figure 2. Summary of detected eQTLs and our predicted power. Columns correspond to the 21 genes we tested for eQTLs. One-sided P-values from linear
models testing the eQTL are summarized by either one (0.05 . P . 0.01), two (0.01 . P . 0.001), or three (0.001 . p) red asterisks; marginally signiﬁcant
tests (0.1 . P . 0.05) are marked with a red dot (see Supplementary Material, Table S1 for all P-values). Blue plus signs indicate the effect is in the same
direction as the effect observed in the LCLs. CEU cell-line r
2 is the proportion of variance explained by genotype in a linear model ﬁt to the original CEU
cell-line data. Estimated power is illustrated with horizontal gray bars for each eQTL-tissue combination using microarray expression data sampled from
CEU HapMap LCLs with matching genotypes (see Materials and Methods), with the axis (ranging from 0 to 1) shown below only for the ﬁrst column.
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required genotype to explain more than 19% of the variance in
expression in the linear model for the CEU population, and for
the P-value for the slope coefﬁcient to be ,0.07 in each of the
YRI (Yoruba in Ibadan, Nigeria) and ASN (pooled Han
Chinese from Beijing, China and Japanese from Tokyo, Japan)
populations for those populations for which the SNP in question
hasbeengenotyped.Wechosethesethresholdstooptimizewhat
weconsideredtheimportantfactorsaffectingourpowertodetect
eQTLs and because we desired a list of approximately 200
eQTLs to pick from. The criteria outlined above resulted in a
SNP associated with each of 206 genes, of which 196 SNPs
were successfully genotyped (Supplementary Material,
Table S1). Genotyping was performed on a Sequenom Mass
Array Genotyping System using methods previously described
(39). Average call rate was 91% (range 3–100%).
Power simulations
Following the genotyping of the 196 eQTLs in our samples,
we performed power simulations using published HapMap
expression data (33) as normalized by (and provided by) (6).
For each candidate SNP, we calculated the number of
samples from our tissue collection possessing each genotype
at that SNP. Then for each genotype, we sampled (without
replacement) an equivalent number of cell-line gene
expression levels from HapMap individuals with matching
genotypes for that SNP. We only considered SNPs with at
least two genotypes, each of which is found in at least two
individuals. For each combination of HapMap population
(from which we sampled expression levels) and SNP, we gen-
erated 1000 replicate samplings. We then estimated power as
the fraction of replicate samplings for which the slope coefﬁ-
cient in a linear model predicting expression with genotype
was signiﬁcant (at the 0.05 level).
Our goal in selecting SNPs was simply to prioritize eQTL
predictions that are likely to be real in the cell lines and for
which we should have decent power to detect in our samples
of primary tissues. We believe that eQTLs detected separately
in multiple HapMap populations are more likely to reﬂect true
functional variation. We hold this view because we are con-
cerned about pursuing falsely inferred eQTLs that are really
attributable to non-genetic batch effects (11). We acknowl-
edge that the possible trade-off of our approach is to miss
population-speciﬁc cis effects (40). Moreover, one important
drawback of a strategy that focuses on eQTLs that are
shared across populations is that we might enrich for effects
attributable to the EBV transformation itself (i.e. artifacts,
which are expected to be shared across populations).
However a substantial enrichment of this sort requires that a
large fraction of real cis eQTLs are population speciﬁc,
which appears unlikely given that only a small proportion of
the variation in gene expression can be attributed to
population-speciﬁc differences (41). Thus we chose to use
both the ASN and YRI populations when we selected the
SNPs (above) as well as in resampling the expression data
Figure 3. Results for two illustrative genes. (A) We detect the cis-eQTL for the gene USMG5 in four of ﬁve tissues while in (B) we do not conﬁrm the eQTL for
the gene DIP2B, despite estimating that we have good power to detect it. The ﬁrst ﬁve panels in parts (A) and (B) correspond to qPCR expression data in the ﬁve
primary tissues (vertical axis on left) while the last panel shows microarray expression data from the original CEU HapMap LCLs (vertical axis on right); note
that we show the CEU cell-line data for comparison purposes—there is no overlap in individuals between cell lines and primary tissues. Black diamonds corre-
spond to normalized expression levels for the genotypes indicated below (number of observations in parenthesis). P-values for the ﬁve tissues are one-sided
( 0.01 , P , 0.05,   0.001 , P , 0.01,    P , 0.001); P-values for the cell-line data are two-sided tests. Power is shown above each plot (vertical axis
ranging between 0 and 1 as indicated) and was estimated by resampling cell-line expression values from each HapMap population in turn (color indicates
HapMap population), conditioning on the genotypes observed for the tissue samples we assayed.
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estimated power conditioning on genotypes from each of the
ﬁve tissues among our samples and each of the three
HapMap populations (CEU, YRI, ASN), resulting in 15
power estimates per gene. We chose the 15 genes with more
than 80% power in at least six population-tissue combinations
and at least 65% power in at least four of the ﬁve CEU tests.
A number of genes fell slightly below one or both of these
cutoffs, but still met our subjective judgment of good candi-
date genes based on the power analyses and the linear
models. So rather than relax the criteria, we manually added
the six genes that looked similarly promising.
We note that our power simulations gave us an estimate of
power assuming that expression in our samples can be
approximated by sampling from the HapMap expression
levels. This approach will tend to overestimate power
because the effect sizes of eQTLs sampled from the tail of
an empirical distribution will tend to be overstated, resulting
in a classic ‘Winner’s Curse’ problem (e.g. 36). It is unclear
how to do power simulations that avoid this feature, as the
underlying effect sizes are unknown.
We calculated the expected number of signiﬁcant tests,
based on our power simulations under two scenarios. First,
we assumed that all eQTLs would be functional in all
tissues with the same effect size as originally seen in the
cell lines. For this we simply summed over tissues our
expected power estimated conditioning on the sample geno-
types, to approximate the total number of eQTLs we would
detect. In the second, equally arbitrary, but perhaps informa-
tive scenario, we assumed that each gene would have a real
eQTL in exactly one of the ﬁve tissues. We estimate the
number of eQTLs we would expect to detect under this scen-
ario by performing the following simulation. For each gene we
chose a tissue to contain the hypothesized real eQTL. We then
sampled HapMap microarray expression data from samples
with matching genotypes at the SNP under consideration,
and used a linear model to test for an association (signiﬁcant
at 0.05 level) between these expression values and the SNP
genotype. For all tests assessing eQTLs that are absent by
hypothesis, we called them signiﬁcant at the false positive
rate of 0.05 (i.e. the probability under the null). We repeated
this procedure for all genes 1000 times, observing the
average number of detected eQTLs.
Assessing effect-size reduction
We estimated how much smaller, on average, the effect sizes
must have been than what we observed in the cell-line data if
we were to only ﬁnd the observed number of eQTLs (19),
assuming all eQTLs were real in all tissues. In brief, for
each eQTL, we use a linear model to partially regress out
the effect of genotype from the HapMap LCL expression
data and determine by how much we would need to reduce
the effect so that on average only 19 of the 105 tests are sig-
niﬁcant. More speciﬁcally, we conducted new power analyses
similar to those above, but instead of resampling the original
microarray expression data from the HapMap LCLs, we
resampled from the residuals of a linear model that entirely
regresses out the effect of genotype from these HapMap
expression data, but then adds back the mean effect and
only a fraction of the genotype effect. In our original power
simulations, the linear model was: yi m þ bg þ 1i and thus
for these power simulations to assess the reduction in effect
size, we used as expression values: 1iþ m þ bfg where yi is
the expression level from the microarray data for individual
i for the gene, and f is the factor by which we reduce the
effect size. We then determine which f in the range of [0.1,
0.9] would result in 19 expected detected eQTLs.
Expression assay and analysis
We used quantitative PCR (qPCR) to measure gene expression
levels. We designed qPCR primers for gene regions within
1 kb upstream of the predicted 30-UTR—within the region
that was originally probed by the microarray (6). Primer
sequences are available upon request. As templates, we used
ﬁrst strand cDNA samples from each tissue. Quantitative
RT-PCR was performed in a 25 mL reaction containing 2X
SYBR master mix (Sigma), 0.2 pM each primer and 1 mL
cDNA template. PCR was performed in a 7900HT Fast Real-
Time PCR System (Applied Biosystems, Inc.). We assayed
each sample in triplicate on the same plate, with three
96-well plates required to assay all the samples for each
gene. Although on each plate we included a dilution series
over four concentrations (1X, 1/5X, 1/25X and 1/125X) to
allow for a plate-speciﬁc estimate of the rate at which the
PCR product accumulates (logr), we found these estimates
to be rather noisy and instead assumed the doubling rate was
identical for all plates (see below). We note that incorporating
the plate-speciﬁc dilution curves in our analyses did not yield
markedly different results.
For normalization, we developed a linear model-based
method that, in effect, normalized our data by all genes.
This linear model estimates the unknown relative, sample-
speciﬁc concentration of cDNA (fis) and the unknown,
plate-speciﬁc ampliﬁcation threshold (Tp) assuming qPCR
ampliﬁcation on plate p of cDNA from individual i from
tissue t using primers for gene g reaches some concentration
Tp at PCR cycle Citg according to the following equation:
Tp¼ Iitg fit r
Citg. Taking the log of both sides and rearranging
gives us a linear model with a response variable proportional
to the cycle number and factors specifying the plate (p) and
sample (s) and residuals corresponding to our estimated log
expression level before ampliﬁcation (Iitg):
ð 1ÞCitg logr  m þ logfitðsÞ logTpðpÞþlogIitg
This linear model, which contains as predictors only two
factors for sample and plate, allows us to remove these
effects and use in all subsequent analysis the residuals,
which represent the log expression level. To then assess the
signiﬁcance of a SNP in explaining variation in expression,
we used a gene/tissue combination-speciﬁc additive linear
model: logIi  m þ bg þ 1, where g is the number of A1
alleles in each individual and errors are normally distributed
with a gene-speciﬁc variance. Signiﬁcant eQTLs are thus
those that have a b coefﬁcient that is signiﬁcantly different
than zero in the direction predicted (6) at the 0.05 test level.
We also consider a linear model for each gene/tissue combi-
nation that includes a dominance coefﬁcient: log Ii  m þ
Human Molecular Genetics, 2009, Vol. 18, No. 22 4301b1g þ b2I(g ¼ 1) þ 1, where g is as before, b2 is the
dominance coefﬁcient and I(g ¼ 1) is the indicator variable
that evaluates to 1 if the individual is heterozygous for the
SNP and 0 if homozygous.
To ensure that the results are robust with respect to the
methodology used, we also tried quantile-normalizing the
negative raw qPCR cycle numbers of each plate, using these
in the above gene-tissue-speciﬁc linear models, and we
observed nearly equivalent results to the above ﬁrst method
(see Supplementary Material, Fig. S2). For quantile normaliza-
tion we normalized to a normal distribution, as the qq-plots
suggested a good ﬁt to a normal.
False discovery rate
We calculated the positive false-discovery rate (35) at a false
positive rate of 0.05 using the qvalue package (version 1.1)
downloaded from CRAN (http://cran.r-project.org/) for the R
programming language (42). We also tested whether our test
is well calibrated by permuting the genotypes and assessing
the number of signiﬁcant tests under this non-parametric null
distribution, and found it to be well calibrated, with, for
example, 5% of the tests signiﬁcant at the 5% test level.
Additionally we calculate the probability that we see 11 or
more eQTLs detected in at least one tissue based on the
assumption of a well-calibrated test, which we assessed for
the 5% level using a permutation method. Thus, under the
null hypothesis of no eQTL in any tissue, each gene has a
1 – 0.95
5¼ 0.226 probability of falsely showing one or more
eQTL. Therefore we calculated the P-value for observing
11 or more genes with one or more eQTL using a binomial
distribution with P ¼ 0.226.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online. Raw data
available at http://giladlab.uchicago.edu/data.html.
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